Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours (Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)

NCT05759923 is registered in ClinicalTrials.gov with Molecure S.A. as lead sponsor.

NCT NCT05759923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours (Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)
Lead sponsor
Molecure S.A.
Phase
Phase 1
Overall status
Recruiting
Start date
January 26, 2023
Completion date
March 31, 2027
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal carcinoma, advanced ovarian carcinoma, advanced pancreatic carcinoma, advanced renal cell carcinoma, metastatic colorectal carcinoma, metastatic ovarian carcinoma, metastatic pancreatic carcinoma, metastatic renal cell carcinoma